Briacell Therapeutics Corp BCTX

$3.40 -0.37 (-9.69%)

Valuation

Market cap: 32,755,000
Revenue TTM: $0
Net income TTM: $-26,310,000
PE ratio: 0.00
Forward PE: —
Profit margin: 0.00%
Debt to equity: 0.00

Trading

Volume: 136,700
Avg volume: 316,000
Day's range: $3.39 – $3.91
Shares out: 8,700,000
Stochastic %K: 1%
Beta: 1.21
Analysts: Strong Buy
Price target: $40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Industry: Biotechnology
Sector: Healthcare
Phone: 604 921 1810
Website: https://briacell.com
Address: Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

No headlines yet.

Stocktwits

JediGreen Oct 17, 6:17 AM

$BCTX https://www.investors.com/news/technology/biotech-stocks-2026-mergers-acquisitions-2027-forecast/

0 replies

JediGreen Oct 17, 4:19 AM

$BCTX This might be a really good sign. I’d consider this shaking the tree 🌳. My opinion someone is trying to get people out to cover or load up or could even be market makers.

0 replies

Biotechlineup Oct 17, 3:29 AM

$BCTX So according to management using present tense language with 177 already enrolled in each arm , the 354 total did truly Hockey stick as they previously stated. I think that went over the analysts head. This is now being driven by the control arm. Very likely management has a good feel for the expectations on the previous year end expectations. Since they said cash run through 2nd qtr and expenses drop rapidly in the observable stage of a trial , all we have to do is wait.

1 replies